Patents by Inventor Seishi Kyoizumi

Seishi Kyoizumi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Monoclonal antibody, its immunoreactive fragment and hybridoma
    Patent number: 7067314
    Abstract: It is an object to utilize a novel HSCA-3 antigen occurring in immature hemopoietic stem cells and a monoclonal antibody recognizing said antigen in 1) the immunoassay or flow cytometry involving antibody labeling and 2) the isolation and purification of immature hemopoietic stem cells from human bone marrow cells, umbilical code blood or blood enriched in human hemopoietic stem cells by mobilization with G-CSF. It is directed to a novel HSCA-3 antigen occurring in immature hemopoietic stem cells and to a monoclonal antibody or an immunoreactive fragment thereof which recognizes said antigen.
    Type: Grant
    Filed: June 18, 2002
    Date of Patent: June 27, 2006
    Assignee: Kaneka Corporation
    Inventors: Takaaki Ohara, Kenji Yamashita, Tetsu Kakutani, Seishi Kyoizumi
  • Antigen and monoclonal antibody which recognizes the antigen
    Publication number: 20020197655
    Abstract: It is an object to utilize a novel HSCA-3 antigen occurring in immature hemopoietic stem cells and a monoclonal antibody recognizing said antigen in 1) the immunoassay or flow cytometry involving antibody labeling and 2) the isolation and purification of immature hemopoietic stem cells from human bone marrow cells, umbilical code blood or blood enriched in human hemopoietic stem cells by mobilization with G-CSF.
    Type: Application
    Filed: June 18, 2002
    Publication date: December 26, 2002
    Applicant: KANEKA CORPORATION
    Inventors: Takaaki Ohara, Kenji Yamashita, Tetsu Kakutani, Seishi Kyoizumi
  • Small animal metastasis model
    Patent number: 5643551
    Abstract: A method for initiating metastasis of human tumor cells under experimental conditions is provided. Immunocompromised non-human mammals having a viable, xenogeneic organ or tissue are used as a host for human tumor cells. The cells are introduced into the chimeric animal after the solid tissue is implanted and are then able to grow and metastasize as they would in situ. Therapeutic regimens may be evaluated in this system to determine efficacy against metastatic processes.
    Type: Grant
    Filed: October 26, 1994
    Date of Patent: July 1, 1997
    Assignee: Systemix, Inc.
    Inventors: Reiko Namikawa, Seishi Kyoizumi, Emilya Shtivelman, Joseph M. McCune
  • In vivo use of human bone marrow for investigation and production
    Patent number: 5633426
    Abstract: Chimeric immunocompromised hosts are provided, comprising human bone marrow of at least 4 weeks from the time of implantation. The bone marrow is found to assume the normal population of bone marrow except for erythrocytes. The bone marrow may be used to study the effect of various agents on the proliferation and differentiation of hematopoietic cells.
    Type: Grant
    Filed: February 10, 1994
    Date of Patent: May 27, 1997
    Assignee: Systemix, Inc.
    Inventors: Reiko Namikawa, Seishi Kyoizumi, Joseph M. McCune, Hideto Kaneshima